RxDoctor Payments DataLook up a doctor →

Karen Barker, MD

Allergy & Immunology · Daphne, ALNPI 1629268263

Payments from drug & device makers

$19,090in general payments, 2019–2025

Across 944 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Sanofi$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Genentech USA, Inc.$1K
  • plus $7K from 38 others

What the payments were for

  • Consulting fees$200%
  • Food & beverage$18,93299%
  • Education$1391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,090 in reported general payments places this provider in the 65th percentile of 30 allergy & immunology providers in Alabama.

See all allergy & immunology providers in Alabama

Medicare billing

Part B allowed, 2024
$88,203
Medicare patients
103
Services billed
5,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab49$189,187
Dupixent SyringeDupilumab30$122,375
TezspireTezepelumab-Ekko26$109,674
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5012$104,753
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$55,930
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$35,637
Combivent RespimatIpratropium/Albuterol Sulfate13$10,058
Epinephrine35$7,347
Breo ElliptaFluticasone/Vilanterol12$7,229
SymbicortBudesonide/Formoterol Fumarate13$4,110
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$2,866
Azelastine Hcl68$2,536
Wixela InhubFluticasone Propion/Salmeterol20$2,000
Fluticasone Propionate95$1,420
Albuterol Sulfate HfaAlbuterol Sulfate68$1,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$3,283$149,42180 claims
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru$1,833$104,75312 claims
GSKTrelegy Ellipta, Breo Ellipta$2,276$63,15985 claims
Boehringer IngelheimCombivent Respimat$350$10,05813 claims
Hikma Pharmaceuticals USAEpinephrine$29$7,34735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 30 allergy & immunology providers in Alabama.

Other allergy & immunology in Daphne

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →